Cemiplimab wins approval for cutaneous SCC

The anti-PD-1 immunotherapy cemiplimab (Libtayo) has been provisionally registered by the TGA for adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC), who are not candidates for curative surgery or curative radiation. According to manufacturer Sanofi Genzyme, cemiplimab is the first medicine provisionally registered for this indication in Australia, via ...

Already a member?

Login to keep reading.

© 2021 the limbic